Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 13/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743611 | 0.85 | HPGD (1.00) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL29687327 | 0.85 | HPGD (1.00) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL30678539 | 0.85 | HPGD (1.00) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL6570578 | 0.84 | KMT2A (0.88) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL763451 | 0.83 | KMT2A (0.86) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL279957 | 0.83 | KMT2A (0.86) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL11918653 | 0.83 | KMT2A (0.86) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL7447564 | 0.82 | KMT2A (0.83) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL15947382 | 0.81 | KMT2A (0.77) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL3408099 | 0.81 | KMT2A (0.81) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758380-B1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9073881-B2 | Benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013041468-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2013-03-28 | — | — | US | disclosed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1780212-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2007-05-02 | — | — | EP | disclosed |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | TEIJIN PHARMA LIMITED | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | KMT2A 2325/4885MEN1 829/4885HPGD 1183/4885 |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | EIF4EBP1, EIF4E, EIF4A2 | KMT2A 1420/4885MEN1 3301/4885HPGD 2620/4885 |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | MAPKAPK2, MAPKAPK5, MAP4K2 | KMT2A 1266/4885MEN1 1494/4885HPGD 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.